Literature DB >> 15720357

Targets and elective colorectal cancer: outcome and symptom delay at surgical resection.

S Bharucha1, S Hughes, V Kenyon, I D Anderson, G L Carlson, N A Scott.   

Abstract

OBJECTIVE: To determine, for elective patients with colorectal cancer, if associations exist between the length of symptom history at surgical resection and Dukes stage, completeness of the surgical procedure and patient survival. PATIENTS AND METHODS: A prospective cohort study was undertaken. Five hundred and eighty-two patients with colorectal cancer, admitted for surgical resection after outpatient consultation, divided into four equal quartiles according to length of symptom history (short: n = 131, 0-103 days; medium: n = 136, 104-177 days; long: n = 136, 178-318 days; very long: n = 137, 319-1997 days). The main outcome measures used were the Extent of tumour (Dukes stage) at resection, completeness of resectional surgery (curative vs palliative), patient survival after resection.
RESULTS: For patients undergoing elective surgical resection of colorectal cancer we did not find an association between Dukes stage and duration of patient history (Dukes stage C tumours were seen in 37% (CI: 26.2%-48.0%) of patients with a short symptomatic history as opposed to 34% (CI: 32%-62%) with a very long symptomatic history). Elective curative resection was not associated with a significantly different symptom duration than elective palliative resection (Palliative resections were performed in 24% (CI: 11.7%-36.4%) of patients with a short symptomatic history as opposed to 16% (CI: 2.4%-29.9%) with a very long symptomatic history). The median survival time for the four elective colorectal patient groups defined by length of symptomatic history was not significantly different - (short: n = 131, 4.3 years; medium: n = 136, 5.9 years; long: n = 136, 7.1 years; very long: n = 137, 5.0 years).
CONCLUSION: Tumour extent, completeness of resection and patient outcome after elective colorectal cancer resection was not found to have an association with length of patient history at the time of surgery.

Entities:  

Mesh:

Year:  2005        PMID: 15720357     DOI: 10.1111/j.1463-1318.2004.00743.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Length of symptoms before referral: prognostic variable for high-grade soft tissue sarcoma?

Authors:  Bruce T Rougraff; Jackie Lawrence; Kenneth Davis
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

2.  Fall of another myth for colon cancer: Duration of symptoms does not differ between right- or left-sided colon cancers.

Authors:  Ersin Öztürk; Mehmet Ayhan Kuzu; Derya Öztuna; Özgen Işık; Aras Emre Canda; Emre Balık; Serdar Erkasap; Tayfun Yoldaş; Cihangir Akyol; Sezai Demirbaş; Bünyamin Özoğul; Ömer Topçu; Ercan Gedik; Bilgi Baca; İlknur Ergüner; Oktar Asoğlu; Bülent Erkek; Tuncay Yılmazlar; Erhan Reis; Rasim Gençosmanoğlu; Ali Konan
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

3.  Delay in Presentation, Diagnosis and Treatment for Colorectal Cancer Patients in Jordan.

Authors:  Munir Ahmad Abu-Helalah; Hussam Ahmad Alshraideh; Moh'd Da'na; Mo'tasem Al-Hanaqtah; Anas Abuseif; Kamal Arqoob; Abdelrahman Ajaj
Journal:  J Gastrointest Cancer       Date:  2016-03

4.  The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.

Authors:  S Stapley; T J Peters; D Sharp; W Hamilton
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

5.  The impact of COVID-19 pandemic on colorectal cancer patients at an NHS Foundation Trust hospital-A retrospective cohort study.

Authors:  Omotara Kafayat Lesi; Ebuwa Igho-Osagie; Sarah-Jane Walton
Journal:  Ann Med Surg (Lond)       Date:  2021-12-15

6.  Do diagnostic delays in cancer matter?

Authors:  R D Neal
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.